NeurologyLive® Friday 5 — February 4, 2022

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 4, 2022.

Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Managing Insomnia: An Overview of Pharmacologic Agents

In episode 12 of this NeurologyLive® Peer Exchange series, "Unmet Needs in Treating Insomnia," a panel of expert physicians offer shared insight on the pharmacologic treatment landscape of insomnia, with a focus on mainstay drug classes.

2: FDA Action Update, January 2022: Approvals, Acceptances, Clinical Holds

Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive® team, including an approval for adults with insomnia, a number of treatment application acceptances for various neuromuscular disorders, and a few clinical holds placed on trials in Alzheimer and Parkinson disease.

3: NeuroVoices: Joanna Hellmuth, MD, MS, on COVID-19 Pathogenesis and Long-Term Cognitive Changes

The cognitive neurologist at the University of California, San Francisco discussed recently published data on the presence of cognitive post-acute sequelae of COVID-19, provided insight on the research needed to explain more about its pathogenesis, and the realistic possibility of developing neurocognitive disorders.

4: People Helping People: Fostering, Supporting, and Empowering Women Leaders in Neurology

Although research illustrates the persistence of inequities between women and men in neurology, Kathleen B. Digre, MD, FAHS; Jessica Ailani, MD, FAHS, FAAN; and Irene A. Malaty, MD shared encouraging thoughts and experiences highlighting the progress made in recent years for National Women Physicians Day.

5: Insights: Aducanumab’s FDA Approval to Treat AD

Alireza Atri, MD, PhD, discusses aducanumab’s recent FDA approval for the treatment of Alzheimer disease and the impact it has had on the landscape of care in episode 4 of this NeurologyLive® Insights series "Testing for Early Diagnosis of Alzheimer’s Disease."

—————————————————